Sebastian Schneeweiß
Sebastian Schneeweiß publishes mostly in Statistics and Probability, Economics and Econometrics and Cardiology and Cardiovascular Medicine, on topics such as Health Systems, Economic Evaluations, Quality of Life, Advanced Causal Inference Techniques and Statistical Methods in Clinical Trials.
- World rank
- #17,575 of 7,710,434 ranked researchers
- Rank in United States
- #6,302 of 1,627,098
- Works
- 812
- Citations
- 51k
- Citations per work
- 63.0
What does Sebastian Schneeweiß research?
Sebastian Schneeweiß's work is mostly in Medicine (22%), Mathematics (14%), Economics, Econometrics and Finance (13%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else40449.7%
- Health Sciences18322.5%
- Medicine18322.5%
- Physical Sciences11714.4%
- Mathematics11714.4%
- Social Sciences10913.4%
- 1Statistics and Probability14% of their works
- 2Economics and Econometrics13% of their works
- 3Cardiology and Cardiovascular Medicine8% of their works
- 4Endocrinology, Diabetes and Metabolism6% of their works
- 5Family Practice5% of their works
- 6Surgery4% of their works
Research topics
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Causal Inference Techniques
- Statistical Methods in Clinical Trials
- Medication Adherence and Compliance
- Diabetes Treatment and Management
- Pharmacovigilance and Adverse Drug Reactions
- Pharmaceutical Economics and Policy
- Pharmaceutical Practices and Patient Outcomes
Which keywords describe Sebastian Schneeweiß's research?
The keywords of their largest research topics: Cost-effectiveness Analysis, Quality of Life, Causal Inference, Propensity Score, Adaptive Designs, False Discovery Rate, Medication Adherence and Treatment Adherence.
- Polypharmacy
- Generic Drugs
- Pharmacovigilance
- Type 2 Diabetes
- Treatment Adherence
- False Discovery Rate
- Propensity Score
- Quality of Life
- Cost-effectiveness Analysis
- Causal Inference
- Adaptive Designs
- Medication Adherence
- Cardiovascular Outcomes
- Adverse Drug Reactions
- Drug Development Costs
- Inappropriate Medication Use
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 16 words, with their numbers
- Cost-effectiveness Analysis1981 topic
- Quality of Life1981 topic
- Causal Inference1711 topic
- Propensity Score1711 topic
- Adaptive Designs1061 topic
- False Discovery Rate1061 topic
- Medication Adherence1001 topic
- Treatment Adherence1001 topic
- Cardiovascular Outcomes981 topic
- Type 2 Diabetes981 topic
- Adverse Drug Reactions731 topic
- Pharmacovigilance731 topic
- Drug Development Costs581 topic
- Generic Drugs581 topic
- Inappropriate Medication Use541 topic
- Polypharmacy541 topic
Where does Sebastian Schneeweiß work?
Sebastian Schneeweiß's main affiliation in the publication record is Brigham and Women's Hospital, United States.
How many publications and citations does Sebastian Schneeweiß have?
OpenAlex counts 812 works and 51,149 citations for Sebastian Schneeweiß, an h-index of 115, ranking #17,575 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Sebastian Schneeweiß. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.